In addition to c-Myc, miR-145 has also been suggested to target the human insulin receptor substrate-1 (IRS-1) and type I insulin-like growth factor receptor (IGF-IR) in colon cancer [25], [27]. Here, IRS1 is linked to malignant colon neoplasm.